Interviews

Ryan Sugarman, MD, discusses the design and purpose of the CheckMate 649 trial for gastroesophageal cancers, gastric cancer, and esophageal adenocarcinoma.

Sophia Kamran, MD, discusses the research supporting the use of trimodality therapy for patients with urothelial cancer.

Nitin Jain, MD, discusses the significance of a study of UCART22, an allogeneic chimeric antigen receptor T-cell therapy for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Ghaith Abu-Zeinah, MD, discusses the unmet needs investigational drugs could address for patients with polycythemia vera.

Tracy L. Rose, MD, MPH, discusses ongoing research in bladder cancer that aims to add onto the standard of care and improve patient outcomes.

Andrew Wei, MBBS, discusses characteristics associated with long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.

John Mascarenhas, MD, summarizes the treatment landscape for myelofibrosis, which now includes of pacritinib.

Naomi B. Haas, MD, discusses the use of VEGF tyrosine kinase inhibitors as neoadjuvant therapy for renal cell carcinoma.

Lee Schwartzberg, MD, discusses the concerns of treating patients with early triple-negative breast cancer with immunotherapy.

Manali Bhave, MD, discusses the updated results of the MonarchE study of abemaciclib in patients with hormone receptor-positive, HER2-negative, breast cancer.

Joseph M. Curry, MD, discusses the introduction of immune checkpoint inhibitors for the treatment of patients with head and neck cancers.

Bishoy M. Faltas, MD, discusses the significance of studying the response of tumor tissue to mutation-targeted agents in urothelial cancer.

Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.

John Mascarenhas, MD, provides advice to oncologists on the use of pacritinib to treatment patients with myelofibrosis and severe thrombocytopenia.

John Mascarenhas, MD, discusses the mechanism of action of pacritinib and how it differs from ruxolitinib and fedratinib.

Solange Peters, MD, PhD, discusses the design of the CheckMate743 study of doublet immunotherapy for patients with malignant pleural mesothelioma.

Jorge Nieva, MD, explains how international drug developers should approach the approval application process after a biologics license application for sintilimab plus chemotherapy for the treatment of nonsquamous non–small cell lung cancer was not successful.

Ronald L. Paquette, MD, discusses characteristics of myelodysplastic syndrome and how they may impact a patient’s success in undergoing stem cell transplant.

Sumanta K. Pal, MD, explains what gastrointestinal cancer research needs to focus on in the near future.

David W. Dougherty, MD, discusses how cancer centers can move forward following the negative effects caused by the COVID-19 pandemic.

Lori A. Leslie, MD, discusses her recent presentation around chimeric antigen receptor T-cell therapy for mantle cell lymphoma and indolent lymphomas.

Thomas Powles, MD, MBBS, MRCP, discusses the implications of the positive outcome of the phase 3 EV-301 trial of enfortumab vedotin in patients with urothelial cancers.

Jorge Nieva, MD, discusses how a future clinical trial of sintilimab injection plus chemotherapy should look in order to achieve FDA approval for the treatment of patients with nonsquamous non–small cell lung cancer.

Daneng Li, MD, discusses the results of the REFLECT trial of lenvatinib in hepatocellular carcinoma.

William H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.

Jorge Nieva, MD, discusses why he voted differently from the other members of the FDA’s Oncologic Drug Advisory Committee regarding sintilimab in combination with chemotherapy for the first-line treatment of patients with nonsquamous non–small cell lung cancer.

Jorge Nieva, MD, discusses what’s needed for frontline sintilimab plus chemotherapy to have a future in United States patients with nonsquamous non–small cell lung cancer after a negative ODAC vote.

Andrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.